KeyCorp, Live Nation, Applied Digital, and Infinity Pharmaceuticals Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings
August 24, 2023 09:44 ET
|
Johnson Fistel, LLP
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital and Infinity and Encourages Investors to Contact the Firm
August 21, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI
August 19, 2023 16:14 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Infinity...
KeyCorp, Live Nation, Applied Digital, and Infinity Pharmaceuticals Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings
August 18, 2023 15:27 ET
|
Johnson Fistel, LLP
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the...
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
August 28, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
August 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Photo Release -- Biopharmaceutical Company Seeks New Sources of Corn Lily
June 22, 2011 10:00 ET
|
Infinity Pharmaceuticals, Inc.
SALT LAKE CITY and BOISE, Idaho, June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, is seeking new sources of a plant commonly known as...
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
June 22, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...
Infinity Reports First Quarter 2011 Financial Results
May 10, 2011 16:00 ET
|
Infinity Pharmaceuticals, Inc.
— Reaffirms 2011 Financial Guidance and Provides Additional Details —
— Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
April 03, 2011 13:36 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...